Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP-R With or Without Oblimersen in Young Patients With Advanced Diffuse Large B-Cell NHL
NCT00080847Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Jun 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Mar 2004; status: terminated.
02
Drugs
oblimersen
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00080847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080847.